MX2015014939A - Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. - Google Patents

Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.

Info

Publication number
MX2015014939A
MX2015014939A MX2015014939A MX2015014939A MX2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A
Authority
MX
Mexico
Prior art keywords
landiolol hydrochloride
blood pressure
heart rate
tachyarrhythmias
long
Prior art date
Application number
MX2015014939A
Other languages
English (en)
Inventor
Günther Krumpl
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48226997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015014939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of MX2015014939A publication Critical patent/MX2015014939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención proporciona un nuevo uso de clorhidrato de landiolol para la reducción persistente de la frecuencia cardíaca durante el período de administración de clorhidrato de landiolol en el tratamiento de un ser humano que sufre de taquicardia, taquiarritmia o presión sanguínea elevada, en donde el clorhidrato de landiolol se administra en una dosis constante de más de 5 µg/kg/min, específicamente de al menos 10 µg/kg/min durante un período de al menos 2 horas y en donde la frecuencia cardíaca y/o presión sanguínea de dicho paciente se reducen de modo persistente durante el período de administración en comparación con la frecuencia cardíaca y/o presión sanguínea antes del tratamiento y no se produce ningún efecto de "overshoot" después de la terminación de dicha administración.
MX2015014939A 2013-04-26 2014-04-25 Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. MX2015014939A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165582.1A EP2796139A1 (en) 2013-04-26 2013-04-26 Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PCT/EP2014/058456 WO2014174076A1 (en) 2013-04-26 2014-04-25 Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias

Publications (1)

Publication Number Publication Date
MX2015014939A true MX2015014939A (es) 2016-01-12

Family

ID=48226997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014939A MX2015014939A (es) 2013-04-26 2014-04-25 Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.

Country Status (28)

Country Link
US (1) US10722516B2 (es)
EP (2) EP2796139A1 (es)
JP (1) JP2016517860A (es)
KR (1) KR102268161B1 (es)
CN (1) CN105324118A (es)
AU (1) AU2014259352B2 (es)
BR (1) BR112015027051A2 (es)
CA (1) CA2910066C (es)
CL (1) CL2015003145A1 (es)
DK (1) DK2988750T3 (es)
EA (1) EA030589B1 (es)
ES (1) ES2906551T3 (es)
HK (1) HK1214511A1 (es)
HR (1) HRP20220470T1 (es)
HU (1) HUE058189T2 (es)
IL (1) IL242220B (es)
LT (1) LT2988750T (es)
MX (1) MX2015014939A (es)
NZ (1) NZ713295A (es)
PH (1) PH12015502465A1 (es)
PL (1) PL2988750T3 (es)
PT (1) PT2988750T (es)
SG (1) SG11201508824RA (es)
SI (1) SI2988750T1 (es)
TN (1) TN2015000480A1 (es)
UA (1) UA117243C2 (es)
WO (1) WO2014174076A1 (es)
ZA (1) ZA201508050B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796139A1 (en) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
CN114031601B (zh) * 2022-01-12 2022-03-18 南京桦冠生物技术有限公司 一种盐酸兰地洛尔的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004323370A (ja) 2003-04-22 2004-11-18 Ono Pharmaceut Co Ltd 麻酔薬と塩酸ランジオロールとを組み合わせてなる併用剤
US20060286037A1 (en) 2003-08-08 2006-12-21 Ono Pharmaceutical Co., Ltd. Heart-slowing drug containing short-acting ß blocker as the active ingredient
JP4784037B2 (ja) 2003-08-27 2011-09-28 独立行政法人国立がん研究センター 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
CN1827109A (zh) 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺
EP2234614B1 (de) * 2007-12-21 2012-10-17 AOP Orphan Pharmaceuticals AG Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamen beta-adrenorezeptor antagonisten
CN101732319B (zh) 2008-11-26 2012-11-07 天津市汉康医药生物技术有限公司 含有盐酸兰地洛尔活性成分的注射用药物组合物及其制备方法
CN102232930B (zh) 2010-05-06 2013-03-27 南京海辰药业有限公司 盐酸兰地洛尔药物组合物及其制备方法
JP2010248263A (ja) 2010-08-04 2010-11-04 National Cancer Center 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
CN102475706A (zh) 2010-11-28 2012-05-30 天津市汉康医药生物技术有限公司 一种供注射用盐酸兰地洛尔药物组合物及其制备方法
EP2796139A1 (en) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias

Also Published As

Publication number Publication date
LT2988750T (lt) 2022-05-10
ES2906551T3 (es) 2022-04-19
DK2988750T3 (da) 2022-04-04
HRP20220470T1 (hr) 2022-05-27
CN105324118A (zh) 2016-02-10
IL242220A0 (en) 2015-11-30
PH12015502465A1 (en) 2016-02-22
CL2015003145A1 (es) 2016-06-24
US20160074411A1 (en) 2016-03-17
EA201592058A1 (ru) 2016-03-31
SG11201508824RA (en) 2015-11-27
EP2796139A1 (en) 2014-10-29
IL242220B (en) 2020-07-30
CA2910066C (en) 2021-10-19
EP2988750A1 (en) 2016-03-02
US10722516B2 (en) 2020-07-28
EA030589B1 (ru) 2018-08-31
PL2988750T3 (pl) 2022-05-16
AU2014259352B2 (en) 2017-03-02
HUE058189T2 (hu) 2022-07-28
CA2910066A1 (en) 2014-10-30
JP2016517860A (ja) 2016-06-20
ZA201508050B (en) 2017-11-29
AU2014259352A1 (en) 2015-11-05
KR20160020411A (ko) 2016-02-23
KR102268161B1 (ko) 2021-06-23
NZ713295A (en) 2020-08-28
HK1214511A1 (zh) 2016-07-29
WO2014174076A1 (en) 2014-10-30
TN2015000480A1 (en) 2017-04-06
UA117243C2 (uk) 2018-07-10
PT2988750T (pt) 2022-03-01
SI2988750T1 (sl) 2022-05-31
EP2988750B1 (en) 2022-01-19
BR112015027051A2 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2019012884A (es) Terapia de combinacion.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
JP2017501154A5 (es)
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2021002090A (es) Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
Morales Bradycardia and hypotension: case report
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
MDS20160124U2 (ro) Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2
MX341960B (es) Composicion farmaceutica para uso en el tratamiento o prevencion de una o varias enfermedaes inflamatorias y/o enfermedades autoinmunitarias.